Top movers in Friday's session
SCYNEXIS Inc SCYX
$4.84
▲ +29.76%
(+$1.11)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$3.60
Prev Close
$3.73
Day Range
$3.60 – $4.95
52W Range
$3.53 – $10.48
Market Cap
$48.06M
Beta
1.11
EPS (TTM)
$-2.92
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-05-02 |
| Shares Out. | 9,930,000 |
| Website | scynexis.com/ ↗ |
| Phone | 12018845485 |
| Employees | 29 |
| Net Income | -$21.3M |
| Total Assets | $77.6M |
| Total Liabilities | $36.3M |
| Equity | $41.3M |
About SCYNEXIS Inc
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
SCYNEXIS Inc is a publicly traded company under the ticker symbol SCYX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)